Biogen and Eisai expand Alzheimer's collaboration

23 October 2017
2019_biotech_test_vial_discovery_big

Japanese and US pharma majors Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) say they have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments.

Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta (Aβ) antibody for patients with Alzheimer’s disease (AD). Perhaps surprisingly, shares of Biogen dipped 2.35% to$330.20 by mid-morning trading today.

Phase III data for aducanumab is expected in late 2019 or early 2020. This "could be one of the first disease-modifying drugs to reach the market," Goldman Sachs analyst Terence Flynn wrote in a note to clients back in the summer. Mr Flynn envisages peak sales of $12 billion for aducanumab.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology